Literature DB >> 1517389

Long term follow-up of Cushing's disease treated with reserpine and pituitary irradiation.

M Murayama1, K Yasuda, Y Minamori, L B Mercado-Asis, N Yamakita, K Miura.   

Abstract

Twenty adult patients with Cushing's disease treated with long term reserpine administration in combination with a single course of external pituitary irradiation were followed. Eleven patients experienced long term remissions of 15.5 +/- 8.9 (mean +/- SD) yr (55%) after a mean irradiation dose of 53.9 +/- 11.4 Gy and a mean duration of reserpine administration of 24.3 +/- 9.3 months. The long term remission rates of the patients irradiated with 50 Gy or less (n = 9; 45.0 +/- 7.1 Gy) and those with more than 50 Gy (n = 10; 61.3 +/- 3.3 Gy; excluding 1 irradiated with 66 Gy who developed brain necrosis) were 56% (5 of 9) and 60% (6 of 10), respectively, and did not differ significantly. There were no significant differences between the 2 groups with regard to the duration of reserpine administration or pretreatment clinical features. At the latest examination, regardless of the irradiation dose, all 9 patients with long term remission showed a higher level of plasma cortisol or 11-hydroxycorticosteroids in the morning than in the evening, normal suppressibility of plasma cortisol with overnight 1 mg dexamethasone (9 of 10), and well preserved responses of other pituitary hormones to various loading tests: normal responses of plasma ACTH to CRH (6 of 9), TSH (7 of 8), and PRL (5 of 8) to TRH and age-related normal responses of GH to GRH (4 of 8), LH (6 of 8), and FSH (6 of 8) to GnRH. These findings suggest that long term reserpine administration in combination with a conventional dose of pituitary irradiation is useful in the treatment of Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517389     DOI: 10.1210/jcem.75.3.1517389

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

2.  Cushing's syndrome caused by an ectopic pituitary adenoma of the sphenoid sinus: Adrenal crisis after partial resections of the adenoma.

Authors:  Hiroyuki Morita; Keigo Yasuda; Kazuya Nkashima; Nobuyasu Noritake; Masanori Murayama; Kuniyasu Shimokawa; Noriyoshi Yamakita; Toshiaki Sano; Nobuaki Sasano; Kiyoshi Miura
Journal:  Endocr Pathol       Date:  1994-06       Impact factor: 3.943

3.  Encouraging efficacy of modern conformal fractionated radiotherapy in patients with uncured Cushing's disease.

Authors:  Sweta Budyal; Anurag R Lila; Rakesh Jalali; Tejpal Gupta; Rajeev Kasliwal; Varsha S Jagtap; Tushar Bandgar; Padmavathy Menon; Nalini S Shah
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

Review 4.  Management of Cushing disease.

Authors:  Nicholas A Tritos; Beverly M K Biller; Brooke Swearingen
Journal:  Nat Rev Endocrinol       Date:  2011-02-08       Impact factor: 43.330

5.  Role of Radiation in the treatment of Cushing Disease.

Authors:  Laurence Katznelson
Journal:  Pituitary       Date:  2022-06-10       Impact factor: 3.599

Review 6.  Radiation therapy for Cushing's disease: a review.

Authors:  Ashraf S Mahmoud-Ahmed; John H Suh
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

7.  Treatment Options in Cushing's Disease.

Authors:  Ahmed Rizk; Juergen Honegger; Monika Milian; Tsambika Psaras
Journal:  Clin Med Insights Oncol       Date:  2012-01-11

8.  Long-term follow-up results of postoperative radiation therapy for Cushing's disease.

Authors:  Giuseppe Minniti; Mattia Osti; Marie Lise Jaffrain-Rea; Vincenzo Esposito; Giampaolo Cantore; Riccardo Maurizi Enrici
Journal:  J Neurooncol       Date:  2007-03-14       Impact factor: 4.506

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.